Table 2.
Summary of Published Reports Providing Data Concerning the Number and Proportion of SAPHO Patients Responsive to bDMARD Therapya
| Reference, year | No. of participants treated with biologic agent | Biologic responders, No. (%) | No. responsive to TNF inhibitor, cumulative subtotal (% of total)b |
|---|---|---|---|
| Ben,14 2010 | 6 | 4 (67) | 4 |
| Aljuhani,15 2015 | 2 | 1 (50) | 5 |
| Li,9 2016 | 41 | 28 (68) | 33 |
| Colina,8 2009 | 9 | 9 (100) | 42 |
| Zwaenep,11 2016 | 3 | 3 (100) | 45 |
| Yap, 2020 (this report) | 13 | 10 (77) | 55/74 (74) |
a
bDMARD, biologic disease-modifying antirheumatic drug; SAPHO, synovitis, acne, pustulosis, hyperostosis, and osteitis; TNF, tumor necrosis factor.
b
This column contains cumulative data, so the percentage is shown only in the final line for the total group.